Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schaar, C.
Right arrow Articles by Kluin-Nelemans, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schaar, C.
Right arrow Articles by Kluin-Nelemans, H.
Haematologica, Vol 90, Issue 10, 1437-1438
Copyright © 2005 by Ferrata Storti Foundation

Comparative Study

Serum syndecan-1 in patients with newly diagnosed monoclonal proteinemia

CG Schaar, HJ Vermeer, PW Wijermans, W Huisman, S le Cessie, and HC Kluin-Nelemans

Serum syndecan-1 was investigated in 189 patients with newly diagnosed monoclonal proteinemia [the diagnoses were multiple myeloma (66), monoclonal gammopathies of undetermined significance (MGUS; n=54), provisional MGUS (no bone marrow examination performed; n=69)] and 36 controls. Syndecan-1 levels ranged widely between all diagnostic categories and were of limited discriminatory value (sensitivity 68%, specificity 78%) in patients with newly diagnosed monoclonal proteinemia.




HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2005 by the Ferrata Storti Foundation.